Effect of pentoxifylline on serum hyaluronic acid in patients with non-alcoholic fatty liver disease

Arab Journal of Gastroenterology

Volumn 10, Issue 3, 2009, Pages 102-105

  Amin, Mona A ^a   Sabry, Dina ^a   Kassem, Mohamed ^b   Amin, Ahmed ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

NAFLD; Pentoxifylline; Serum hyaluronic acid

Indexed keywords

HYALURONIC ACID; PENTOXIFYLLINE; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFECT; ECHOGRAPHY; HUMAN; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 70749101752     PISSN: 16871979     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajg.2009.09.001     Document Type: Article

References (14)

1. Sanyal A.J., Campbell Sargent C., Mirshahi F., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120 5 (2001) 1183-1192
2. Rockey D.C., Boyles J.K., Gabbiani G., et al. Rat hepatic lipocytes express smooth muscle actin upon activation in vivo and in culture. J Submicrosc Cytol Pathol 24 2 (1992) 193-203
3. Preaux A.M., Mallat A., Rosenbaum J., et al. Pentoxifylline inhibits growth and collagen synthesis of cultured human hepatic myofibroblast-like cells. Hepatology 26 2 (1997) 315-322
4. + exchanger modulates the fibrogenic effect of oxidative stress in rat hepatic stellate cells. J Hepatol 30 5 (1999) 868-875
5. Day C.P., and James O.F. Steatohepatitis: a tale of two "hits"?. Gastroenterology 114 4 (1998) 842-845
6. Chitturi S., and Farrell G.C. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 21 1 (2001) 27-41
7. Satapathy S.K., Garg S., Chauhan R., et al. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol 99 10 (2004) 1946-1952
8. Klein C., and Gerken G. Invasive versus nicht-invasive verlaufskontrolle - scores als histologieersatz bei chronischer hepatitis? [Evaluation of non-invasive scores in the follow-up of chronic hepatitis]. Schweiz Rundsch Med Prax 94 16 (2005) 645-647
9. Kaneda H., Hashimoto E., Yatsuji S., et al. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 21 9 (2006) 1459-1465
10. Khan J.A., Khan F.A., Dilawar M., et al. Serum hyaluronic acid as a marker of hepatic fibrosis. J Coll Physicians Surg Pak 17 6 (2007) 323-326
11. Falck Ytter Y., Younossi Z.M., Marchesini G., et al. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 21 1 (2001) 17-26
12. Adams L.A., Zein C.O., Angulo P., et al. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 99 12 (2004) 2365-2368
13. Lee Y.M., Sutedja D.S., Wai C.T., et al. A randomized controlled pilot study of pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatol Int 2 2 (2008) 196-201
14. Satapathy S.K., Sakhuja P., Malhotra V., et al. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 22 5 (2007) 634-638